{"brief_title": "ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past", "brief_summary": "The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).", "detailed_description": "All patients take ABT-378/ritonavir and efavirenz; there are no placebos in this study. Patients take study medications for 48 weeks, during which time there will be 15 study visits. There is a possibility of a study extension after 48 weeks.", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Lopinavir/Ritonavir", "Efavirenz"], "criteria": "Inclusion Criteria Patients may be eligible for this study if they: - Are HIV-positive. - Have a viral load (level of HIV in the blood) of at least 1,000 copies/ml. - Have been receiving stable (no changes) anti-HIV treatment that includes at least 1 PI for at least 8 weeks prior to study entry. - Have received more than 1 PI for at least 12 weeks each at some time in the past. Exclusion Criteria Patients will not be eligible for this study if they: - Have had any active opportunistic (AIDS-related) infections within the past 30 days. - Have ever received nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as delavirdine, nevirapine, or efavirenz. - Have received certain medications. - Are pregnant or breast-feeding. - Abuse alcohol or drugs.", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "efavirenz", "mesh_term": ["HIV Infections", "Ritonavir", "Lopinavir", "HIV Protease Inhibitors", "Efavirenz", "Protease Inhibitors"], "id": "NCT00004582"}